Figure 2.
Unadjusted primary combined outcome parameters of stroke or systemic embolism in patients with and without significant valvular disease (SVD) randomized to either rivaroxaban or warfarin.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.